Gavin Wright
YOU?
Author Swipe
View article: Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors Open
View article: Phase 2 Dose-Ranging Trial of VGT-309 for Molecular Imaging of Cancer during Pulmonary Resection
Phase 2 Dose-Ranging Trial of VGT-309 for Molecular Imaging of Cancer during Pulmonary Resection Open
Objectives VGT-309 (abenacianine) is being evaluated as an intraoperative molecular imaging (IMI) agent. This phase 2, open-label, dose-ranging study evaluated efficacy and safety in participants undergoing surgical resection of suspicious…
View article: Impact of Stage‐Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia
Impact of Stage‐Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia Open
Introduction Lung cancer accounts for 9% of all cancer diagnoses in Australia with a 5‐year survival rate of 26%. Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer, representing 15% of all lung cancer cases and a 5‐…
View article: Prognosis of surgically resected clinical stage 1A non-small cell lung cancers manifesting as a subsolid nodule on computed tomography including pure ground glass nodules
Prognosis of surgically resected clinical stage 1A non-small cell lung cancers manifesting as a subsolid nodule on computed tomography including pure ground glass nodules Open
This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To quantify the risk of tumour relapse/recurrence after a surgical resection of stage 1A non-small cell lung cancer (NSCLC) as manifested on computed tomo…
View article: Smoking Cessation Practices in Australian Oncology Settings: A Cross‐Sectional Study of Who, How, and When
Smoking Cessation Practices in Australian Oncology Settings: A Cross‐Sectional Study of Who, How, and When Open
Purpose Patients who smoke tobacco during and after a cancer diagnosis have poorer health outcomes. Oncology healthcare providers (HCPs) are crucial to providing smoking cessation support. The study examined the characteristics associated …
View article: A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking
A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking Open
Aim Smoking is a chronic relapsing condition that is under‐reported in oncology settings. People who report current smoking (CS) and those who report recently quitting smoking (RQ) should receive cessation support when they are diagnosed w…
View article: Disparities in Timeliness and Guideline-Concordant Treatment is Associated with Excess Mortality in Public Versus Private Lung Cancer Patients
Disparities in Timeliness and Guideline-Concordant Treatment is Associated with Excess Mortality in Public Versus Private Lung Cancer Patients Open
View article: Home-Based Exercise and Self-Management After Lung Cancer Resection
Home-Based Exercise and Self-Management After Lung Cancer Resection Open
Importance Patients with lung cancer have poor physical functioning and quality of life. Despite promising outcomes for those who undertake exercise programs, implementation into practice of previously tested hospital-based programs is rar…
View article: <i>TERT</i> Expression and Clinical Outcome in Pulmonary Carcinoids
<i>TERT</i> Expression and Clinical Outcome in Pulmonary Carcinoids Open
PURPOSE The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs …
View article: 385. TRANSLATING MOLECULAR-TARGETING FLUORESCENT PROBES IN OESOPHAGEAL CANCER PRE-CLINICAL MODELS
385. TRANSLATING MOLECULAR-TARGETING FLUORESCENT PROBES IN OESOPHAGEAL CANCER PRE-CLINICAL MODELS Open
Background Intra-operative molecular imaging (IMI) is an emerging field that utilises tumour-targeting fluorescent probes to improve oncological outcomes. A novel class of probe known as quenched activity-based probes (qABP), developed to …
View article: Lung cancer (internet‐based) Delphi (<scp>LUCiD</scp>): A modified <scp>eDelphi</scp> consensus process to establish Australasian clinical quality indicators for thoracic cancer
Lung cancer (internet‐based) Delphi (<span>LUCiD</span>): A modified <span>eDelphi</span> consensus process to establish Australasian clinical quality indicators for thoracic cancer Open
Background and Objective Approximately 16,000 new cases of lung cancer are diagnosed each year in Australia and Aotearoa New Zealand, and it is the leading cause of cancer death in the region. Unwarranted variation in lung cancer care and …
View article: Trends in primary care blood tests prior to lung and colorectal cancer diagnosis—A retrospective cohort study using linked Australian data
Trends in primary care blood tests prior to lung and colorectal cancer diagnosis—A retrospective cohort study using linked Australian data Open
Introduction Abnormal results in common blood tests may occur several months before lung cancer (LC) and colorectal cancer (CRC) diagnosis. Identifying early blood markers of cancer and distinct blood test signatures could support earlier …
View article: Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial Open
Background Liver disease is within the top five causes of premature death in adults. Deaths caused by complications of cirrhosis continue to rise, whilst deaths related to other non-liver disease areas are declining. Portal hypertension is…
View article: Management of malignant pleural effusion and trapped lung: a survey of respiratory physicians and thoracic surgeons in Australasia
Management of malignant pleural effusion and trapped lung: a survey of respiratory physicians and thoracic surgeons in Australasia Open
Background Malignant pleural effusions (MPEs) are common, and a third of them have underlying trapped lung (TL). Management of MPE and TL is suspected to be heterogeneous. Understanding current practices in Australasia is important in guid…
View article: Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening
Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening Open
View article: Trends in primary care blood tests prior to lung and colorectal cancer diagnosis – a retrospective cohort study using linked Australian data
Trends in primary care blood tests prior to lung and colorectal cancer diagnosis – a retrospective cohort study using linked Australian data Open
View article: Stage-Specific Guideline Concordant Treatment Impacts on Survival in Non-Small Cell Lung Cancer: A Novel Quality Indicator
Stage-Specific Guideline Concordant Treatment Impacts on Survival in Non-Small Cell Lung Cancer: A Novel Quality Indicator Open
View article: MA11.06 Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer
MA11.06 Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer Open
View article: Supplementary Tables from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
Supplementary Tables from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma Open
XLSX file 75K, This is an excel file containing 9 sheets, one for each of the 9 supplementary tables (S1 to S9) mentioned in the main text
View article: Table 2 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Table 2 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Supplementary Table S2: GO term enrichment analysis of differentially expressed genes between t1 and t0, overlapping in PDX 788, 926, 792
View article: Data from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Data from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Lung squamous cell carcinoma (SqCC) is a molecularly complex and genomically unstable disease. No targeted therapy is currently approved for lung SqCC, although potential oncogenic drivers of SqCC have been identified, including amplificat…
View article: Supplementary Figures from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
Supplementary Figures from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma Open
PDF file 234K, This is a file containing the list of supplementary tables, the list of supplementary figures, as well as the 7 supplementary figures (S1 to S7) and their correspondent legends, mentioned in the main text
View article: Data from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Data from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Lung squamous cell carcinoma (SqCC) is a molecularly complex and genomically unstable disease. No targeted therapy is currently approved for lung SqCC, although potential oncogenic drivers of SqCC have been identified, including amplificat…
View article: Table 2 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Table 2 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Supplementary Table S2: GO term enrichment analysis of differentially expressed genes between t1 and t0, overlapping in PDX 788, 926, 792
View article: Figure S1-S6 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Figure S1-S6 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Supplementary Fig. S1. Generation of patient-derived xenografts from surgery and biopsy specimens of non small cell lung cancer Supplementary Fig. S2. Squamous cell carcinoma patient-derived xenografts recapitulate the genomic phenotype of…
View article: Data from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
Data from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma Open
We discovered a novel somatic gene fusion, CD74–NRG1, by transcriptome sequencing of 25 lung adenocarcinomas of never smokers. By screening 102 lung adenocarcinomas negative for known oncogenic alterations, we found four additional …
View article: Supplementary Tables S1, S3-S7, Supplementary Material and Methods, and Supplementary Figure Legends from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Supplementary Tables S1, S3-S7, Supplementary Material and Methods, and Supplementary Figure Legends from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Supplementary Table 1. Engraftment rates of lung cancer patient-derived xenografts vary according to histology and specimen type; Supplementary Table 3. TP53 mutations in primary lung cancer and corresponding PDX, as detected by exome sequ…
View article: Data from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
Data from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma Open
We discovered a novel somatic gene fusion, CD74–NRG1, by transcriptome sequencing of 25 lung adenocarcinomas of never smokers. By screening 102 lung adenocarcinomas negative for known oncogenic alterations, we found four additional …
View article: Supplementary Tables from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
Supplementary Tables from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma Open
XLSX file 75K, This is an excel file containing 9 sheets, one for each of the 9 supplementary tables (S1 to S9) mentioned in the main text
View article: Supplementary Tables S1, S3-S7, Supplementary Material and Methods, and Supplementary Figure Legends from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Supplementary Tables S1, S3-S7, Supplementary Material and Methods, and Supplementary Figure Legends from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma Open
Supplementary Table 1. Engraftment rates of lung cancer patient-derived xenografts vary according to histology and specimen type; Supplementary Table 3. TP53 mutations in primary lung cancer and corresponding PDX, as detected by exome sequ…